ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Summary

This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)

Timeline

Start

2023-09-14

Primary completion

2027-06-30

Completion

2028-06-30

Publications

• Bandi DSR, Sarvesh S, Nagaraju GP, Kim H, Foote J, Bae S, Yoon KJ, Malla M, Masood A, Akce M, Liu ZR, El-Rayes BF. ProAgio, a Novel Integrin alphavbeta3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment. bioRxiv [Preprint]. 2026 Jan 16:2026.01.15.699725. doi: 10.64898/2026.01.15.699725.

Drugs

Indications